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E-mail address: bianchi16@unisi.it (E. Bianchi).Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of a painful
peripheral neuropathy which is reproduced in rodent animal models with features observed in humans.
Our focus was to explore the alterations of intracellular second messengers at supraspinal level in oxa-
liplatin-induced mechanical hyperalgesia. In our experiments, chronic administration of oxaliplatin to
rats induced mechanical hyperalgesia which lasted for many days. When the hyperalgesic rats were sub-
mitted to paw pressure test in the presence of selective PKC inhibitor Calphostin C supraspinally admin-
istered, hyperalgesic effect could be reversed showing that PKC activity in supraspinal brain regions is
needed. Concurrently, oxaliplatin chronic treatment induced a specific upregulation of c isoforms of
PKC and increased phosphorylation of c/e PKC isoforms within thalamus and PAG. Phosphorylation
was reversed when PKC activity was inhibited by Calphostin C. Distinct PKC-activated MAPK pathways,
including p38MAPK, ERK1/2 and JNK, were investigated in chronic oxaliplatin rat. A dramatic phosphor-
ylation increase, Calphostin C sensitive, could be observed in thalamus and PAG for p38MAPK. These data
show that, in oxaliplatin-induced neuropathy, enhanced mechanical nociception is strictly correlated
with increased phosphorylation of specific intracellular mediators in PAG and thalamus brain regions
pointing to a role of these supraspinal centers in oxaliplatin-induced neuropathic pain mechanism.
 2009 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
Oxaliplatin[(trans-l)1,2-diaminocyclohexaneoxalatoplatinum(II)]
is a platinum-based chemotherapy drug whose cytotoxicity is
thought to result frominhibitionofDNAsynthesis. Theuseof theanti-
neoplastic drug oxaliplatin for the treatment of a variety of cancers is
significantly limited by the development of a painful peripheral neu-
ropathy characterized by both an acute sensitivity to cold and lack of
sensation in the hands and feet and a chronic foot/leg, hand/arm
numbness [3]. It has previously been reported that oxaliplatin pro-
duces a peripheral neuropathy in rats in several well-characterized
animal models with features observed in humans [5]. Thus, oxalipla-
tin induces acute mechanical hyperalgesia after intravenous single
dose administration [11]; repeated intravenous oxaliplatin enhances
mechanical hyperalgesia and allodynia, heat allodynia and cold allo-
dynia in rodents [2] indicating sensitization in theperipheral andcen-
tral nociceptive system. Although the mechanism lying beneath the
acute neuronal excitability and pain induced by oxaliplatin is still to
bedetermined, it has been ascribed, at least in part, to a specific inter-
action of oxaliplatin with specific isoforms of the voltage-gated so-
dium channels, located in the cellular membrane, increasing thefor the Study of Pain. Published by
iversità di Siena/Dipartimen-excitability of sensory neurons, an effect that has been suggested to
play a role in pain syndrome experienced by oncologic patients
[9,10]. Although investigations of themechanismof neuropathic pain
induced by platinum-based chemotherapy drug have been a major
focus of interest for the last years, neuropathic pain is amajor chronic
condition that presently remains difficult to treat for solid tumor che-
motherapy. In the present study we tested whether alterations of
intracellular second messengers at supraspinal level are revealed in
oxaliplatin-induced mechanical hyperalgesia.2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats weighing between 200 and 300 g
(Harlan Inc., Varese, Italy) were used. During the experiment, the
animals were fed with commercial cubes and drinkable water ad
libitum and maintained in an air-conditioned housing room
(23 ± 1 C) with a 12-h light–dark cycle. All animal procedures
were performed according to the European Economic Community
(EEC) guidelines for animal care (DL 116/92, application of the
European Communities Council Directive of 24 November 1986-
86/609/EEC). Ethical policy of the University of Florence conforms
with the Guide for the Care and Use of Laboratory Animals of the
US National Institutes of Health (NIH Publication No. 85-23,Elsevier B.V. All rights reserved.
Fig. 1. Time-course of mechanical hyperalgesia induced by oxaliplatin treatment.
Effect of administration of oxaliplatin in comparison with administration of saline
on mechanical hyperalgesia. Each point is the mean ± SEM of single mechanical
nociceptive threshold obtained from at least 15 animals. *p < 0.05 significantly
different from control saline. ^ indicates oxaliplatin 2.4 mg/kg i.p. administration.
Fig. 3. Time-course of rat weight during repeated oxaliplatin administration. Graph
describes weight increase of treated with respect to control rats. Each point
represents the mean ± SEM of all treated rats. *p < 0.05, **p < 0.01 significantly
different from saline-treated rats.
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01). All efforts were made to minimize animal suffering and to re-
duce the number of animals used.
2.2. Drug administration
Oxaliplatin was purchased from Sequoia Research Product Ltd.,
USA, and administered by intraperitoneal injection (i.p.) at the
dose of 2.4 mg/kg i.p. for five consecutive days every week (15
injections) according to a previously established treatment proto-
col [2]. Calphostin C was purchased from Calbiochem (USA) and
intracerebroventricularly (i.c.v.) administered. Oxaliplatin was
dissolved in 10 ml/kg saline volume; Calphostin C was dissolved
in saline added to 0.5% DMSO and administered at 5 ll/rat
volume.Fig. 2. Effect of Calphostin C on mechanical hyperalgesia induced by chronic
oxaliplatin treatment. Mechanical hyperalgesia induced by oxaliplatin treatment is
shown in the presence or absence of i.c.v. Calphostin C administration at different
doses. Experiments were performed on day 21 after the start of oxaliplatin
administration. Each point represents the mean ± SEM of at least eight rats. *p < 0.05
significantly different from saline-treated rats. Vehicle, saline + 0.5% DMSO; Oxa,
oxaliplatin; Calph., Calphostin C.2.3. Intracerebroventricular injection technique
Rats, anesthetized with chloral hydrate (400 mg/kg i.p.) and lo-
cated in a stereotaxic frame (Stellar, Stoelting, Wood Dale, IL, USA),
were implanted with a plastic guide cannula (Metalant, Sweden)
stereotaxically inserted through a skull hole drilled over the left
lateral ventricle of the brain, AP = 0.8, L = 1.5 mm relative to
the bregma, according to data from Paxinos and Watson [15].
The cannula was screwed into the skull hole until it reached a
depth of 1 mm below the external surface of the skull and was se-
cured to the bone with dental cement. After surgery, the rats were
allowed to recover for 3 days in individual plastic cages. Saline,
vehicle and drug solutions were injected in awake rats using a
Hamilton 10-ll syringe that was inserted through the guide can-
nula to a depth of 3.8 mm below the external surface of the skull.
The needle was left in situ for 30 s to allow the drug to diffuse.
2.4. Paw pressure test
The experimentswere performed blind in a quiet roomwith ran-
domization of treatment. Rats were habituated to handling by the
investigator during the week before the experiments. The nocicep-
tive threshold in rat was determined with an analgesimeter (Ugo
Basile, Varese, Italy), according to themethod described by LeightonFig. 4. Lack of effect of oxaliplatin treatment on rat motor coordination (rota-rod
test). Graph shows that in saline and oxaliplatin-treated rat the number of falls in
30 s decreased every following session without any significant difference among
the control and treated groups before starting of treatment (0 day), at the end of
treatment (21st day) and 9 days after the end of treatment. Each point represents
the mean ± SEM of at least 15 rats.
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small area of the dorsal surface of the paw using a blunt conical
probe. Mechanical pressure was increased until vocalization or a
withdrawal reflex occurred while the rat was lightly restrained.
Vocalization or withdrawal reflex thresholds were expressed in
gram. An arbitrary cut-off value of 250 g was adopted. Two series
of rats were administered with oxaliplatin or saline at t + 0 of each
treatment day. Nociceptive threshold was measured in rats 2 h be-
fore the end of days 1, 7, 14, 17, 19, 21, 22, 23, 26, 27 and 30.
2.5. Rota-rod test
The apparatus consisted of a base platform and a rotating rod
with a diameter of 6 cm and a non-slippery surface. The rod was
placed at a height of 30 cm from the base. The rod, 40 cm in length,
was divided into five equal sections by six disks. The speed of the
apparatus is 16 r.p.m. The integrity of motor coordination was as-
sessed on the basis of the number of falls from the rod in 30 s
according to Vaught et al. [21]. Those rats scoring less than 3 and
more than 6 falls in the pretest were rejected. The performance
time was measured before (pretest) and 15, 30, 45 and 60 min after
the beginning of the test.Fig. 5. Western blot assay of PKC and MAPK protein level in different brain regions. Effec
in different brain regions in comparison with saline treatment are reported in (a). Effect
p38MAPK (43 kDa) level is reported in (b). Each bar represents the mean ± SEM of dens
achieved from five pooled animals; density level is expressed for each considered brain r
(37 kDa) (b). Homogenates from each single experiment were submitted at least three ti
representative Western blot of a single experiment is visible at the bottom. TC, thalamu
cortex oxaliplatin; PC, PAG control; PO, PAG oxaliplatin; SC, striatum control and SO, st2.6. Western immunoblotting
At 21st day after oxaliplatin treatment started, the rats used for
these experiments were decapitated under ethyl oxide anesthetic
and the brain dissected, placed on dry ice and then stored at
80 C. Various brain areas from control and treated rats were dis-
sected on a cold plate. The tissue was mechanically homogenized
in ice with lysis buffer containing 1 M Tris–HCl (pH 7.5), 10% so-
dium dodecyl sulfate (SDS), 40 mM p-nitrophenyl phosphate
(PNFF), 57 mM phenylmethylsulfonyl fluoride (PMSF), 100 mM so-
dium orthovanadate (Na3VO4), 100 mM sodium pyrophosphate
(NaPP), 1.4 mg/ml aprotinin, 2 mg/ml leupeptine, 1 M NaCl,
100 mM EGTA and 50 mM EDTA. Homogenates were centrifuged
at 10,000g for 15 min at 4 C. The supernatant was collected and
then stored at 80 C. Protein concentration of the total fraction
was quantified using Bradford’s method (Protein Assay kit, Bio-
Rad, Laboratories, Milan, Italy). Protein homogenates (30–100 lg)
from control and oxaliplatin-treated rats were separated on 10%
SDS–PAGE and transferred onto nitrocellulose membranes
(110 min at 120 V) using standard procedures. Membranes were
blocked in PBST 0.1% (PBS containing 0.1% Tween) containing 5%
non-fat dry milk for 120 min. After washing, blots were incubatedt of chronic oxaliplatin treatment on PKCc (80 kDa) and PKCe (85 kDa) protein level
of chronic oxaliplatin treatment on ERK1/2 (42–44 kDa), SAPK/JNK (46–54 kDa) and
ity level obtained from three independent experiments. Each single experiment is
egion as percent of the control saline normalized to b-actin (43 kDa) (a) and GAPDH
mes to Western blotting. *p < 0.05, ***p < 0.001 significantly different from control. A
s control; TO, thalamus oxaliplatin; CC, pre-frontal cortex control; CO, pre-frontal
riatum oxaliplatin.
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lated on Thr514 (p-PKCc, 1:1000 dilution) (Biosource, Camarillo,
CA, USA); PCKc (1:1000), PCKe phosphorylated on Ser729 (p-PCKe,
1:750), PKCe (1:800) (Santa Cruz Biotechnology Inc., CA, USA);
p38MAPK phosphorylated on Thr180/Tyr182 (p-p38MAPK
1:250), p38MAPK (1:500), ERK1/2 phosphorylated on Thr202/
Tyr204 (p-ERK1/2 1:500), ERK1/2 (1:500), SAPK/JNK phosphory-
lated on Thr183/Tyr185 (p-SAPK/JNK 1:750) and SAPK/JNK
(1:750) (Cell Signaling Technology). After being washed with PBS
containing 0.1% Tween, the nitrocellulose membrane was incu-
bated with goat anti-rabbit horseradish peroxidase-conjugated
secondary antiserum (1:2000–1:5000) (Santa Cruz Biotechnology
Inc., CA, USA) and left for 1–2 h at room temperature. Blots were
then extensively washed according to the manufacturer’s instruc-
tion and developed using enhanced chemiluminescence detection
system (Millipore, Milan, Italy) or with colorimetric method
(Opti-4CN substrate Kit Bio-Rad, USA). Densitometric analysis of
scanned images was performed on a Macintosh iMac computer.
Measurements in control samples were assigned a relative value
of 100% b-Actin and glyceraldehydes-3-phosphate-dehydrogenase
(GAPDH) were used as loading controls, respectively, for PKC and
MAPK.Fig. 6. Western blot assay of phosphorylated PKC and MAPK level in different brain regi
brain regions in comparison with saline treatment is reported in (a). Effect of chronic oxal
reported in (b). Each bar represents the mean ± SEM of density level obtained from thr
animals. Density analysis was performed as previously. *p < 0.05, **p < 0.01, ***p < 0.00
experiment is visible at the bottom. TC, thalamus control; TO, thalamus oxaliplatin; CC, pr
oxaliplatin; SC, striatum control and SO, striatum oxaliplatin.2.7. Statistical analysis
All experimental results are given as mean + SEM. Analysis of
variance ANOVA, followed by Fisher’s post hoc comparison, was
used to verify significance between two means. Data were ana-
lyzed with the StatView software for the Macintosh (1992). p val-
ues of less than 0.05 were considered significant.
3. Results
3.1. Effect of oxaliplatin on mechanical nociceptive threshold
The mean baseline paw-withdrawal threshold of oxaliplatin-
treated rats was not significantly different from that of control
rats until 14th day after treatment started (Fig. 1). After that,
paw-withdrawal threshold gradually decreased to lower mechan-
ical nociceptive threshold (i.e., hyperalgesia) which lasted for
1 week after the end of treatment (Fig. 1). Baseline paw-with-
drawal threshold was restored at 9th day after completion of
oxaliplatin administration. When the oxaliplatin-treated rats
were i.c.v. administered with protein kinase C (PKC)-specific
inhibitor Calphostin C at different doses and then submitted toons. Effect of chronic oxaliplatin treatment on p-PKCc and p-PKCe level in different
iplatin treatment on p-ERK1/2, p-SAPK/JNK and p-p38MAPK phosphorylation level is
ee independent experiments. Each single experiment is obtained from five pooled
1 significantly different from control. A representative Western blot of a single
e-frontal cortex control; CO, pre-frontal cortex oxaliplatin; PC, PAG control; PO, PAG
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higher Calphostin C dose. Calphostin C, when administered alone,
did not induce any significant difference with respect to basal va-
lue (Fig. 2).3.2. Effect of oxaliplatin on rat weight
Before initiation of oxaliplatin administration, the control and
oxaliplatin-treated rats weighted, respectively, 214.4 ± 3.3 and
218.0 ± 4.1 g. Animals in treated and control group gained weight
comparable throughout the first 2 weeks of the study. At the third
week, the weight increase was significantly lower in oxaliplatin-
treated rats (Fig. 3).3.3. Rota-rod
The endurance time on the rotating rod, evaluated immediately
before and 15, 30, 45 and 60 min at the end of the 3-week treat-
ment (21st day) showed a lack of any impairment in the motor
coordination of control and treated animals (Fig. 4). The same test
performed before starting and 9 days after the end of treatment did
not show any significant difference in motor coordination between
treated and control groups.Fig. 7. Effect of Calphostin C on PKCc, PKCe and p38MAPK phosphorylation level. Den
thalamus after saline/control, oxaliplatin treatment in the presence or absence of Calpho
mean ± SEM of at least five animals. Brain areas have been dissected at the time of the m
***p < 0.001 significantly different from saline/control and ^p < 0.05, ^^p < 0.01, ^^^p < 0
oxaliplatin; TC + C, thalamus oxaliplatin + Calphostin C.3.4. PKC protein and phosphorylation level in chronic oxaliplatin-
administered rat
Western analysis of PKC protein level was performed in thala-
mus, periaqueductal gray (PAG) matter, cortex and striatum sam-
ples from 21-day treated and control rats. There was a higher
level of c isoform of PKC in thalamus and PAG whereas e level
was not significantly different from control (Fig. 5a). A significant
increase with respect to control was detected in thalamus and
PAG for both c and e isoforms when phosphorylated, respectively,
on Thr514 and Ser729 (Fig. 6a). Phosphorylated PKCc level was
significantly higher with respect to control in striatum (Fig. 6a).
In the presence of PKC inhibitor Calphostin C, phosphorylation
levels were completely or partially reversed to control value,
respectively, in thalamus and PAG for PKCc; phosphorylation
levels returned to basal PKCe value (Fig. 7). PKC phosphorylation
level did not show any significant difference from control in the
sample from spinal cord for both c and e isoforms (Fig. 8).
3.5. p38MAPK protein and phosphorylation level in chronic
oxaliplatin-administered rat
p38MAPK protein level was not significantly different from con-
trol in the considered brain regions (Fig. 5b). Phosphorylatedsity analysis of PKCc, PKCe and p38MAPK phosphorylated form level in PAG and
stin C (200 ng/rat i.c.v.) is represented in the upper figure. Each bar represents the
aximum effect (90 min after the administration of Calphostin C). *p < 0.05, **p < 0.01,
.001 significantly different from oxaliplatin. TC, thalamus control; TO, thalamus
Fig. 8. Phosphorylation level of PKC and MAPK protein levels in the spinal cord.
Effect of oxaliplatin treatment on p-PKCc, p-PKCe, p-ERK1/2, p-SAPK/JNK and p-
p38MAPK level in comparison with saline treatment. Results are expressed as the
mean ± SEM of five different animals. Density level is expressed for each protein as
percent of the control saline normalized to b-actin and GAPDH. ***p < 0.001
significantly different from saline/control. SCC, spinal cord control; SCO, spinal
cord oxaliplatin.
146 M. Norcini et al. / PAIN 146 (2009) 141–147p38MAPK level dramatically increased in PAG and thalamus
(Fig. 6b); a significant increase was detected in striatal area
(Fig. 6b). Calphostin C administration completely and partially re-
versed these values to control, respectively, in thalamus and PAG
samples (Fig. 7). No significant change in phosphorylation could
be detected in spinal cord (Fig. 8).
3.6. ERK1/2 and SAPK/JNK protein and phosphorylation level in chronic
oxaliplatin-administered rat
ERK1/2 and SAPK/JNK protein levels were not significantly dif-
ferent from control in the considered brain regions except in stria-
tumwhere a mild significant increase could be detected for ERK1/2
(Fig. 5b). Phosphorylated ERK1/2 level significantly increased in
cortex and decreased in striatum, thalamus and PAG (Fig. 6b).
Phosphorylated SAPK/JNK level highly significantly increased in
striatum and cortex whereas decreased in thalamus (Fig. 6b). Phos-
phorylation increase was revealed in spinal cord for ERK1/2 (Fig. 8).
4. Discussion
In our experiments, chronic administration of oxaliplatin to rats
induced mechanical hyperalgesia as expected [12]. Oxaliplatin-
treated rats showed no relapse in general status; weight time
course of oxaliplatin-treated rats paralleled controls until 15th
day after starting of the treatment even if weight increase was low-
er in treated animals at the time point 18–21 days. Since an altered
motor coordination could lead to a misinterpretation of the results
obtained, a rota-rod test was therefore performed and any alter-ation of the motor activity induced by chronic oxaliplatin adminis-
tration was excluded. The neurotoxicity induced by oxaliplatin in
humans and rodents is paired with a long time course painful
peripheral hyperalgesia which often disappears within a few days
to several weeks reappearing with repeat cycles of chemotherapy
[11]. In our experiments, administration of oxaliplatin to rats five
times a week for 2 weeks did not induce any significant change
in paw pressure threshold. During the third week of treatment,
paw-withdrawal threshold gradually decreased reaching values
corresponding to the hyperalgesic state which lasted for many
days after the end of treatment before returning to basal value. A
significant difference in the intensity of hyperalgesia could not
be found between the earlier and the later times after last oxalipl-
atin administration. We tested whether intracellular second
messenger contributes to oxaliplatin-induced mechanical hyperal-
gesia in rats which were in a hyperalgesic state and were no more
submitted to oxaliplatin administration from two days. When
hyperalgesic rats were submitted to paw pressure in the presence
of selective PKC inhibitor Calphostin C supraspinally administered,
hyperalgesic effect could be reversed at the higher dose. This find-
ing suggests that PKC activity in brain regions must be required to
maintain the mechanical hyperalgesic state. Western blots, probed
with specific antibodies, demonstrated that oxaliplatin chronic
treatment induced a region-specific upregulation of c isoforms of
PKC within thalamus and PAG. Both these brain sites are impli-
cated in nociceptive transmission, with the thalamus being the
main termination site for spinothalamic pathway and the brain-
stem containing important descending modulatory structures such
as PAG [8]. Western blots were also probed with polyclonal anti-
bodies that specifically detect phosphorylation of Thr514 and
Ser729, respectively, on c and e PKC isoforms. A dramatic phos-
phorylation increase for both isoforms could be observed in PAG
from chronic oxaliplatin-treated rat. A significant increase was also
observed in thalamus for both isoforms and in striatum only for
PKCc. Both c and e isoforms of PKC have been previously shown
to be implicated in hyperalgesia [1,7]. A number of studies over
the last several years indicate that brainstem descending pathways
linking the PAG, the rostral ventromedial medulla (RVM) and the
spinal cord constitute a major mechanism in the modulation of
pain transmission [8]. In addition to descending inhibition, recent
studies indicate that persistent pain after tissue or nerve injury is
linked to an enhanced activation of descending modulatory influ-
ences from the brainstem or forebrain. Particularly, an increased
net descending facilitatory drive leads to an amplification and
spread of the pain [16,17,19,20]. When phosphorylation was inves-
tigated in rats chronically treated with oxaliplatin in the presence
of PKC inhibitor Calphostin C supraspinally administered at the
highest dose, PKCc/e phosphorylation was partially reversed in
PAG and completely in thalamus suggesting that these isoforms
of PKC are implicated in hyperalgesic effects induced by oxaliplatin
administration. Activation of the PKC pathway can lead to phos-
phorylation of several intracellular targets recruiting distinct
MAPK pathways, including p38MAPK, ERK1/2 and JNK. These
MAPK pathways play a role as regulators of nociceptive sensitivity
in various models of inflammatory pain and hyperalgesia to
mechanical and thermal stimuli [14]. In our experiments, Western
blot protein level detection of ERK, SAPK/JNK and p38MAPK was
unmodified with respect to control in thalamus, PAG and cortex
from chronic oxaliplatin rats. Phosphorylation level of these mole-
cules decreased in thalamus for ERK and SAPK/JNK and in PAG and
striatum for ERK whereas increased consistently in cortex and stri-
atum for SAPK/JNK and mildly for ERK in spinal cord as previously
shown in other kinds of neuropathic pain [4,6,18]. A dramatic in-
crease in p38MAPK phosphorylated form could be observed in
thalamus and PAG. These data show for the first time that
alterations in protein and phosphorylation level of intracellular
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by chronic oxaliplatin administration to rats. When PKC was inhib-
ited at supraspinal sites by the administration of Calphostin C to
rats previously chronically administered with oxaliplatin, a partial
whereas significant reversion of phosphorylation in p38MAPK was
obtained in PAG and thalamus whereas phosphorylation did not
decline in other assayed signaling molecules. These data show that,
in oxaliplatin-induced neuropathy, enhanced mechanical nocicep-
tion is strictly correlated with increased phosphorylation of spe-
cific intracellular mediators in PAG and thalamus brain regions
pointing to a role of these supraspinal centers in oxaliplatin-in-
duced neuropathic pain mechanism through PKC/p38MAPKmolec-
ular signaling. Pharmacological modulation of these intracellular
mediators may open the door for novel analgesic effective in oxa-
liplatin-induced neuropathic pain.
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